CHENGDU, Chine, 19 mars 2023 /PRNewswire/ — Keymed Biosciences Inc. (HKEX: 02162) a annoncé ses résultats annuels pour 2022. Axée sur les besoins cliniques non satisfaits, la Société a continué de développer efficacement des pipelines novateurs et différenciés, de mener de façon…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.